Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer
作者： Mhd Yaser Al-Marrawi , Bikramajit Singh Saroya , Matthew C Brennan , Zhaohai Yang , Thomas M Dykes
DOI: 10.4161/CBT.25191
关键词:
摘要: … recently approved multi-kinase inhibitor with structure very similar to sorafenib. After three and a half months of monotherapy on regorafenib the EGFR inhibitor panitumumab (6 mg/kg …
elsevier.com
sci-hub.se 参考文章(29)
Jamal Joudeh, Joshua E. Allen, Avisnata Das, Varun Prabhu, Michael Farbaniec, Jeffrey Adler, Wafik S. El-Deiry, Novel antineoplastics targeting genetic changes in colorectal cancer. Advances in Experimental Medicine and Biology. ,vol. 779, pp. 1- 34 ,(2013) , 10.1007/978-1-4614-6176-0_1
John P. Plastaras, Seok-Hyun Kim, Yingqiu Y. Liu, David T. Dicker, Jay F. Dorsey, James McDonough, George Cerniglia, Ramji R. Rajendran, Anjali Gupta, Anil K. Rustgi, J. Alan Diehl, Charles D. Smith, Keith T. Flaherty, Wafik S. El-Deiry, Cell Cycle–Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation Cancer Research. ,vol. 67, pp. 9443- 9454 ,(2007) , 10.1158/0008-5472.CAN-07-1473
G.K. Abou-Alfa, S. Ricci, D. Amadori, A. Santoro, A. Figer, J. De Greve, J. Douillard, M. Moscovici, B. Schwartz, L.B. Saltz, 42 Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC) Ejc Supplements. ,vol. 2, pp. 16- 17 ,(2004) , 10.1016/S1359-6349(04)80050-8
Scott M. Wilhelm, Lila Adnane, Philippa Newell, Augusto Villanueva, Josep M. Llovet, Mark Lynch, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Molecular Cancer Therapeutics. ,vol. 7, pp. 3129- 3140 ,(2008) , 10.1158/1535-7163.MCT-08-0013
A. A. Adjei, Blocking oncogenic Ras signaling for cancer therapy. Journal of the National Cancer Institute. ,vol. 93, pp. 1062- 1074 ,(2001) , 10.1093/JNCI/93.14.1062
Petra Kupsch, Bernhard F. Henning, Katrin Passarge, Heike Richly, Katrin Wiesemann, Ralf A. Hilger, Max E. Scheulen, Olaf Christensen, Erich Brendel, Brian Schwartz, Elke Hofstra, Rudolf Voigtmann, Siegfried Seeber, Dirk Strumberg, Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clinical Colorectal Cancer. ,vol. 5, pp. 188- 196 ,(2005) , 10.3816/CCC.2005.N.030
Anirudh Prahallad, Chong Sun, Sidong Huang, Federica Di Nicolantonio, Ramon Salazar, Davide Zecchin, Roderick L. Beijersbergen, Alberto Bardelli, René Bernards, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature. ,vol. 483, pp. 100- 103 ,(2012) , 10.1038/NATURE10868
A Awada, A Hendlisz, T Gil, S Bartholomeus, M Mano, D de Valeriola, D Strumberg, E Brendel, C G Haase, B Schwartz, M Piccart, Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours British Journal of Cancer. ,vol. 92, pp. 1855- 1861 ,(2005) , 10.1038/SJ.BJC.6602584
R.A. Hilger, M.E. Scheulen, D. Strumberg, The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. ,vol. 25, pp. 511- 518 ,(2002) , 10.1159/000068621
Martina Heim, Mariam Scharifi, Jochen Zisowsky, Ulrich Jaehde, Dimitris Voliotis, Siegfried Seeber, Dirk Strumberg, The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anti-Cancer Drugs. ,vol. 16, pp. 129- 136 ,(2005) , 10.1097/00001813-200502000-00003